A CBD/THC Combination Did Not Significantly Improve Chemotherapy-Induced Nerve Damage in a Rigorous Trial | Research

The takeaway

In a 12-week randomized double-blind trial, a CBD/THC combination did not significantly improve the primary outcome of sensory neuropathy symptoms in cancer patients with chemotherapy-induced peripheral neuropathy, though some secondary measures trended toward improvement.

Oncologists, cancer patients with neuropathy considering cannabinoids, and clinical researchers designing cannabinoid trials.

What the researchers found

The active group receiving CBD (125.3–135.9 mg) combined with THC (6.0–10.8 mg) in gelcaps did not show statistically significant improvement on the primary outcome (QLQ-CIPN20 sensory subscale) compared to placebo over 12 weeks, though some secondary endpoints suggested potential trends.

Why it matters

This is one of the first rigorous RCTs testing cannabinoids for CIPN. While the negative primary result is disappointing, it provides crucial evidence to temper enthusiasm from smaller, uncontrolled studies and helps define where future research should focus.

The numbers in context

12-week double-blind RCT. Active: CBD 125.3–135.9 mg + THC 6.0–10.8 mg in gelcaps. Cancer types: breast, colorectal, endometrial, ovarian. CIPN grade 2–3. Primary outcome (CIPN20 sensory): not significantly different from placebo.

How the study worked

12-week randomized, double-blind, placebo-controlled trial in patients with nonmetastatic breast, colorectal, endometrial, or ovarian cancer experiencing grade 2–3 CIPN from taxane- or platinum-based chemotherapy. Active arm received CBD (125.3–135.9 mg) + THC (6.0–10.8 mg) in gelcaps. Primary outcome: QLQ-CIPN20 sensory subscale.

What this study cannot tell us

Specific formulation and dose may not represent optimal cannabinoid therapy for CIPN. Duration (12 weeks) may be insufficient. Grade 2–3 CIPN may be harder to treat than earlier stages. Sample characteristics not fully described in abstract.

How to read the evidence

Gold-standard randomized, double-blind, placebo-controlled trial providing high-quality evidence for this specific formulation and indication.

When this study was published

Published 2025.

The bigger picture

In an era of cannabis hype for many conditions, negative results from rigorous trials are essential for evidence-based medicine. This doesn't mean cannabinoids can't help CIPN — it means this specific formulation and dose may not be sufficient, and future trials should explore different approaches.

Questions still open

Would higher doses or different THC:CBD ratios be more effective? Is topical rather than oral administration better for peripheral neuropathy? Should future trials target earlier-stage CIPN? Are there subgroups who benefited?

Common questions

Does this mean cannabis doesn't help with chemo nerve damage?

It means this specific CBD/THC formulation at this dose didn't beat placebo for sensory neuropathy over 12 weeks. Different doses, routes (topical), or formulations might perform differently. More research is needed.

Why did earlier studies show cannabis helps neuropathy?

Earlier studies were often smaller, uncontrolled, or used different outcomes. Rigorous double-blind trials sometimes don't replicate initial positive results because they control for placebo effects, which can be substantial in pain research.

Read the original research

Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial.

Frontiers in oncology, 15, 1590168

View on PubMed ↗Publisher’s paper ↗

Citation

Weiss, Marisa; Giaddui, Muath; Kjelstrom, Stephanie; Gary, Joseph; Ward, Sara Jane; Burrell, Jessica; Diguilio, Katherine; Bidas, Gabrielle; Erebor, Ebuwa; Meske, Sam; Saeed, Lisa; Windawi, Sarah; Aliano Ruiz, Katherine; Ghaneie, Arezoo; Hibbs, Julianne; Marks, John; Holtz, David; Ali, Zonera; Shevade, Aarthi; Sabol, Jennifer; Ciocca, Robin; Zeger, Eric; Gilman, Paul; Larson, Sharon; Shimamoto, Shoichi; Martinez, Diana. (2025). Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial.. Frontiers in oncology, 15, 1590168. https://doi.org/10.3389/fonc.2025.1590168